SCHEMBL4201322

SCHEMBL4201322

CC(=O)N1CCCN(c2ccc3c(n2)CCN(C(=O)OC(C)(C)C)CC3)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.51
SKP1 P63208 2/20 0.51
SKP2 Q13309 2/20 0.51
MAP4K4 O95819 1/20 0.48
PDE10A Q9Y233 1/20 0.45
MAPT P10636 4/20 0.45
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ESR2 Q92731 1/20 0.42
GPR119 Q8TDV5 4/20 0.42
NR1H2 P55055 1/20 0.42
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
GALR2 O43603 1/20 0.40
GALR1 P47211 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
SUV39H2 Q9H5I1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8054507 0.96 MAP4K4 (0.51) CKS1BSKP1SKP2MAP4K4MAPT
SCHEMBL4205087 0.90 MAP4K4 (0.48) CKS1BSKP1SKP2MAP4K4PDE10A
SCHEMBL4208933 0.89 CKS1B (0.48) CKS1BSKP1SKP2MAP4K4PDE10A
SCHEMBL4213013 0.89 MAP4K4 (0.47) CKS1BSKP1SKP2MAP4K4PDE10A
SCHEMBL4203740 0.89 MAP4K4 (0.47) CKS1BSKP1SKP2MAP4K4PDE10A
SCHEMBL4215873 0.87 MAP4K4 (0.51) CKS1BSKP1SKP2MAP4K4MAPT
SCHEMBL13568089 0.87 MAP4K4 (0.50) CKS1BSKP1SKP2MAP4K4MAPT
SCHEMBL13568087 0.85 MAP4K4 (0.49) CKS1BSKP1SKP2MAP4K4MAPT
SCHEMBL4195090 0.83 USP2 (0.46) CKS1BSKP1SKP2MAP4K4MAPT
SCHEMBL4205072 0.83 HTR2A (0.53) CKS1BSKP1SKP2MAP4K4PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS CASCADE THERAPEUTICS INC. (CA) 2009-12-17 US disclosed
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS CASCADE THERAPEUTICS INC. (CA) 2009-12-17 US disclosed
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS CASCADE THERAPEUTICS INC. (CA) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS HTR2C, HTR2A, HTR5A CKS1B 4494/4885SKP1 4858/4885SKP2 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.